{"page":{"totalFilteredElements":330},"studies":[{"active":true,"description":"<div>Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE)</div>","eudractNumber":"2021-000330-33","id":6920,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym2","name":"Morbus Hodgkin"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04837859","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-12-06T12:52:07+01:00","shortTitle":"INDIE","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Klinische Forschungsplattform zur \nErfassung der Entscheidungsfindung in der Biomarker-basierten \nPr&#228;zisionsonkologie und deren klinische Bedeutung","eudractNumber":null,"id":5702,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04389541","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-07-13T08:22:15+02:00","shortTitle":"INFINITY","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab&#160;Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With&#160;Previously Untreated Advanced Melanoma (PRISM-MEL-301)","eudractNumber":"2023-505306-42","id":9869,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"},{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"}],"nctNumber":"NCT06112314","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-06T09:44:34+01:00","shortTitle":"Immunocore IMC-F106C-301","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"The Registry of the European Mantle Cell Lymphoma Network (EMCL-R)","eudractNumber":null,"id":8672,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-01-24T09:08:41+01:00","shortTitle":"International MCL Registry (EMCL-R)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Nicht-interventionelle Beobachtungsstudie zur Bewertung der Lebensqualit&#228;t (HRQoL) bei Patienten mit rezidiviertem und/oder refrakt&#228;rem Multiplen Myelom, die eine vorherige Therapielinie erhalten haben und mit Isatuximab behandelt werden.","eudractNumber":null,"id":12318,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-05-27T10:21:06+02:00","shortTitle":"IsaPRO","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Jade - Klinische Forschungsplattform zur Behandlung und zum Ergebnis bei Patienten mit hepatozellul&#228;rem oder cholangiozellul&#228;rem Krebs<br />","eudractNumber":null,"id":6544,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04510740","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-08-31T09:02:52+02:00","shortTitle":"JADE - Registerplattform Leberkrebs","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors","eudractNumber":"2024-513285-19-00","id":10011,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"NRAS","id":"mt_6"},{"name":"KRAS","id":"mt_7"},{"name":"HRAS","id":"mt_70"},{"name":"KRAS-G12C","id":"mt_250"}],"nctNumber":"NCT06026410","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2026-06-01T14:46:47+02:00","shortTitle":"KO-2806-001","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"A Phase III, Randomized, open-label study evaluating the efficacy and safety of Divarasib and Pembrolizumab versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in patients with previously untreated, KRAS G12C-mutated, advanced or metastatic non-squamous non&#8722;small cell lung cancer","eudractNumber":"2024-518365-10-00","id":11679,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"KRAS-G12C","id":"mt_250"}],"nctNumber":"NCT06793215","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-01T12:35:09+01:00","shortTitle":"KRAScendo 2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"<div>A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma</div>","eudractNumber":"2020-000562-41","id":7242,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04989803","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2023-01-01T09:01:37+01:00","shortTitle":"KT-US-499-0150","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants with Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy","eudractNumber":"2025-524403-80-00","id":11989,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07479797","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-09-29T08:37:13+02:00","shortTitle":"KT-US-740-0603 PALISADES-2","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]}]}